Patents by Inventor Zachary E. R. Newby

Zachary E. R. Newby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
    Patent number: 11806335
    Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: November 7, 2023
    Assignee: Lilac Therapeutics, Inc.
    Inventors: Hongyan Guo, Amy S. Lee, Hyung-Jung Pyun, Devleena M. Shivakumar, Manoj C. Desai, Lianhong Xu, John E. Knox, Zachary E R Newby
  • 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS
    Publication number: 20220106276
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 7, 2022
    Inventors: Muzaffar ALAM, Leah CLEARY, Melissa FLEURY, Zhonghua PEI, Richard STEEL, James SUTTON, John E. KNOX, Zachary E. R. NEWBY
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11130759
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 28, 2021
    Assignee: IDEAYA BIOSCIENCE, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11084798
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 10, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11046691
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: June 29, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby